Objective: To understand the action mechanisms of artesunate on inhibiting leukaemia cell line K562 on the molecular level.

Method: The gene chip was used to detect the expression panel of genes of leukaemia cell line K562 treated by dihydroartemisinin. K562 cells were treated with 1 x 10(-5), 4 x 10(-5), 16 x 10(-5), 64 x 10(-5), 256 x 10(-5) mol x L(-1) dihydroartemisinin for 24 h, and then studied the modality changes by invert microscope. The morphological changes of the nucleons were observed by Hoechst33342/PI staining. The cell cycle were examined by flow cytometry analysis (FCM). Total RNA samples were obtained by TRIzol and were reverse transcribed to the cDNA. The cDNA samples were hybridized to our gene chips. Hybridization signal were collected and analyzed following scanning by Gene Pix 4100A.

Result: The numbers of drift cells were increased and the density of cells was decreased under invert microscope after K562 cells were treated with dihydroartemisinin for 24 h. Morphological changes of cell apoptosis such as karyopyknosis and conglomeration were observed by Hoechst 33342/PI staining. Flow cytometric analysis showed that cells were arrested in G2 phase. There were 13 differentially expressed genes identified. Hybridization analysis showed up-regulation of chk1 and down-regulation of PCNA, cyclinB1, cyclinD1, cyclinE1, cdk4, cdk2, E2F1, DNA-PK, DNA-Topo I, mcl-1, jNK, VEGF in the dihydroartemisinin-treated K562 cells.

Conclusion: Dihydroartemisinin can Inhibit the leukaemia cell line K562 and exert its anti-cancer effect by altering the expression of these genes involved in cell cycle; dihydroartemisinin may act via apoptosis pathway.

Download full-text PDF

Source

Publication Analysis

Top Keywords

leukaemia cell
12
cell k562
12
10-5 10-5
12
action mechanisms
8
treated dihydroartemisinin
8
k562 cells
8
cells treated
8
invert microscope
8
morphological changes
8
cell cycle
8

Similar Publications

Unlabelled: Biochemical analyses of cerebrospinal fluid (CSF) are routinely performed at diagnosis in many pediatric oncology and hematology centers when acute leukemia is diagnosed. However, the clinical relevance of these analyses remains unclear. We conducted a retrospective analysis of biochemical CSF data from children diagnosed with acute leukemia at two French hospitals between 2016 and 2023 assessing the results in relation to the presence or absence of leukemic neuromeningeal involvement and the correlation between cytological and biochemical analyses.

View Article and Find Full Text PDF

Background: Esophageal squamous cell carcinoma (ESCC) stands as the sixth most common cause of cancer-related mortality on a global scale, with a strikingly high proportion-over half-of these fatalities occurring within China. The emergence of radiation resistance in ESCC patients significantly diminishes overall survival rates, complicating treatment regimens and reducing clinical outcomes. There is an urgent need to explore the molecular mechanisms that underpin radiation resistance in ESCC, which could lead to the identification of new therapeutic targets aimed at overcoming this resistance.

View Article and Find Full Text PDF

LncRNA HOXA10-AS as a novel biomarker and therapeutic target in human cancers.

Front Mol Biosci

January 2025

Department of Immunology, School of Clinical and Basic Medical Sciences, Shandong First Medical University, Jinan, Shandong, China.

Long non-coding RNAs (lncRNAs) are crucial regulatory molecules that participate in numerous cellular development processes, and they have gathered much interest recently. HOXA10 antisense RNA (HOXA10-AS, also known as HOXA-AS4) is a novel lncRNA that was identified to be dysregulated in some prevalent malignancies. In this review, the clinical significance of HOXA10-AS for the prognosis of various cancers is analyzed.

View Article and Find Full Text PDF

Multiple myeloma is a disease related to the proliferation of malignant plasma cells; in most patients, the disease is confined to the level of bone marrow. However, in a minority of patients, the malignant plasma cells are also localized outside the bone marrow, either at the level of peripheral blood (plasma cell leukemia) or at the level of soft tissues (extramedullary multiple myeloma). These two rare forms of aggressive MM (ultrahigh-risk (uHR) MM as MM leading to death within 24-36 months) are both associated with some molecular features and with a limited response to current treatments.

View Article and Find Full Text PDF

Background: Clonal mature B-cell lymphoproliferative disorders (B-LPDs) are a heterogeneous group of neoplasia characterized by the proliferation of mature B lymphocytes in the peripheral blood, bone marrow and/or lymphoid tissues. B-LPDs classification into different subtypes and their diagnosis is based on a multiparametric approach. However, accurate diagnosis may be challenging, especially in cases of ambiguous interpretation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!